MétaCan
Menu
← Back to cohort

Androgen suppression combined with elective nodal irradiation and dose escalated prostate treatment: A non-inferiority, phase III randomized controlled trial of stereotactic body radiation therapy versus brachytherapy boost in patients with unfavourable risk localized prostate cancer (ASCENDE-SBRT; CCTG PR24; NCT06235697).

2025· article· en· W4410809351 on OpenAlexafffundabout
Andrew Loblaw, Rachel Glicksman, Joelle Helou, Winkle Kwan, Gerard Morton, Tamim Niazi, Melanie Davidson, M. Neil Reaume, Alexander W. Wyatt, Constance Laroche-Lefebvre, Keyue Ding, Wendy R. Parulekar

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Diagnosis and Treatment
Canadian institutionsUniversity of British ColumbiaMcGill UniversityUniversity of OttawaJewish General HospitalBC Cancer AgencyPrincess Margaret Cancer CentreUniversity Health NetworkHealth Sciences CentreQueen's UniversityCancer Care OntarioSunnybrook Health Science Centre
FundersCanadian Institutes of Health Research
KeywordsMedicineAndrogen suppressionProstate cancerRandomized controlled trialBrachytherapyProstateRadiation therapyNuclear medicineOncologyRadiosurgeryAndrogen deprivation therapyUrologyInternal medicineRadiologyCancer

Abstract

fetched live from OpenAlex

TPS5132 Background: External beam radiotherapy (EBRT), brachytherapy boost and androgen deprivation therapy (ADT) is the evidence-based standard of care for unfavourable (unfavourable intermediate, high and very high) risk non-metastatic prostate cancer. Preliminary data demonstrate that treatment with 5 fractions of stereotactic body radiotherapy (SBRT) delivered to the pelvis and prostate with ADT is efficacious and tolerable in this patient population (Murthy Int J Rad Onc Biol Phys 2025) Other potential advantages associated with this treatment strategy include fewer treatment visits, lower cost, avoidance of a general anesthetic and decreased resource utilization. Rigorous evaluation of this treatment strategy within a clinical trial is required to inform adoption in practice. Methods: PR24 is a Canadian Cancer Trials Group led, intergroup, randomized phase III, non-inferiority study comparing pelvic EBRT + brachytherapy boost to SBRT (5 fractions delivering 40Gy to prostate and 25Gy to pelvis) in brachytherapy eligible, unfavourable risk, non-metastatic prostate cancer patients. All patients will receive risk-adapted duration of ADT. The primary objective is to determine if SBRT is non-inferior to conventional EBRT with brachytherapy boost in terms of disease progression free survival (PFS). Secondary objectives include a comparison between arms of: safety and tolerability; efficacy including PSA response rate at 4 years, metastasis-free survival, prostate cancer cause-specific survival, overall survival; patient-reported and economic outcomes. Biobanking for future correlative studies is included in study design. Statistical design : The target accrual is 710 patients over 3.6 years with 5-year follow-up up to rule out a target HR 1.65 (6.5% inferiority difference at 5-years) in PFS, using type 1 error rate 5% (one sided) and 80% power with 5% lost to follow-up. Conduct to Date : Study activation - March 2024. First patient enrolled - April 2024. Accrual to date: 45. Supported by CIHR grant #183644, NCTN grant #CA180863 and CCS grant #707213. Clinical trial information: NCT06235697 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.010
Threshold uncertainty score0.032

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0020.001
Open science0.0020.001
Research integrity0.0020.005
Insufficient payload (model declined to judge)0.0100.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.388
Teacher spread0.368 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Diagnosis and Treatment→French-language works237,207→